CEO Christina Östberg Lloyd will be one of the speakers in the “Follow the money” session at SwedenBIO Summit on December 9. In an interview by SwedenBIO, Christina talks about her first few weeks as CEO of Pharmiva after eleven years as Medical and Clinical Director at Novo Nordisk.
– For the first three to four weeks, there has been full focus on preparing and conducting an investment round, a pre-IPO. There is a great interest. Getting to know the company’s employees and their skills, taking in all knowledge of the conditions and regulations for a company of this type and understanding how to manage a successful IPO, takes all my time now. In short, to learn to operate on a new playing field.
On December 9, you are one of the speakers in the session “Follow the money” at SwedenBIO Summit. What do you hope to have accomplished by then?
– Then we have worked through a clear and sustainable strategy. The pre-IPO will be closed, and we are in full swing with the preparations for our upcoming IPO. By then, we will also have kicked off a planned study and worked on optimizing the production. In parallel, the work of mapping relevant communication channels and building on our network continues.
CEO Christina Österberg Lloyd
SwedenBIO is the national non-profit association for the life science industry in Sweden, with almost 300 members. Sweden has an innovative life science industry, strong academia and world leading infrastructure for research. SwedenBIO represent the leading life science companies in Sweden. Their members are companies active within pharma, biotech, diagnostics and medtech and comprise the entire range from small start-ups, to SMEs and large enterprises. Many are engaged in research and development. Other members are experts in fields such as IP, law, finance, product development, life science communication and business development.